Article Text

Download PDFPDF
Prognostic factors and adjuvant treatment in early epithelial ovarian cancer
  1. K. Bertelsen,
  2. B. HØLund,
  3. J. E. Andersen,
  4. K. Nielsen,
  5. I. StrØYer and
  6. P. Ladehoff
  1. Department of Oncology, Odense University Hospital, DK-5000, Denmark
  1. Address for correspondence: Kamma Bertlesen, Department of Oncology, Odense University Hospital, DK-5OOO, Denmark.


Four hundred and ten patients with epithelial ovarian cancer FIGO stages I and II were registered by a Danish multicenter study group (The Danish Ovarian Cancer Group - DACOVA). Two-thirds were stage I, the most frequent substage was Iai which was the classification in 27%. Five-year survival for stage I was 72%, and 38% for stage II. Multivariate analysis showed that age, stage, residual tumor, histologic grade and adjuvant treatment had prognostic value. For stage, three significantly different groups could be identified: (1) stage Iai, (2) stage Iaii-Ic, and (3) stage II. Histologic grade showed a significant survival difference between all grades. Adjuvant treatment had a moderate but significant impact on survival. Patients in stage Iai had a good survival with surgery alone and will probably not benefit from adjuvant therapy. Adjuvant treatment improved survival for the remaining patients in stages I and II without residual tumor. A difference between treatment modalities was not observed. However, the data need to be confirmed by a randomized trial. Patients in stage II with residual tumor should be treated as stage III.

  • early ovarian cancer
  • prognostic factors.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.